Jan. 29, 2014
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Cleveland BioLabs, Inc. ("Cleveland BioLabs" or the "Company") (NasdaqCM: CBLI). Such investors are advised to contact
or his investor Relation's coordinator
The investigation concerns whether Cleveland BioLabs and certain of its officers and/or directors have violated federal securities laws. Specifically, the investigation focuses on certain statements contained in the Registration Statement issued in connection with the Company's
January 14, 2014
, public securities offering, related to funding from the Biomedical Advanced Research Development Authority.
January 23, 2014
, Cleveland BioLabs announced that the Biomedical Advanced Research Development Authority "terminated negotiations related to the company's proposal for further development of Entolimod as a medical radiation countermeasure."
If you are aware of any facts relating to this investigation, or purchased shares of Cleveland BioLabs pursuant to the Offering and suffered losses on that investment, you can assist this investigation by contacting
or his Investor Relations Coordinator
of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email
. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC
SOURCE Bronstein, Gewirtz & Grossman, LLC